Researchers report hopeful progress in efforts to find treatments for Alzheimer’s disease. They report a recent clinical ...

A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

A new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...

There is a potential link between Alzheimer's disease and the herpes simplex virus-1 (HSV-1), which is a common cause for ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer's disease ... more options and greater opportunity to have more time. Having multiple treatment options ...

Having multiple treatment options is the kind of advancement ... showed physical changes that happen in the brain due to Alzheimer’s disease. “Defining diseases by the biology has long been ...

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer’s disease. “The EMA filing acceptance for blarcamesine to review the ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Former study was recently accepted in a peer-reviewed medical journal with focus on Alzheimer’s disease titled, “Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ...